"TET [Gossen M, Bujard H, Proceedings of the
"Artificial insemination (AI) of cattle is the major reproduction technology used in modern stock farming. In northern and western European countries the artificial inseminated reproduction of diary cattle exceeds 95%. The success of AI is strongly dependent on a precise determination of ovulation and a temporally coordinated insemination. The efficiency of AI is limited by the sperm survival in utero, which is compromised by leucocyte mediated phagocytosis and sperm retrograde transport, limiting the fertilization period to approximately 20 hours. As a result, the rate of successful artificially inseminated cows (non-return rate) does not exceed 70%. The ovulation in mammalian is a complex and primarily hormone-controlled process that plays a critical role in reproductive physiology. Initiation of ovulation is stimulated by a strong and highly specific preovulatory surge of the pituitary luteinizing hormone (LH). The LH binds to the luteinizing hormone receptor (LHR) that is expressed on the granulosa and theca cells of the mature preovulatory ovarian follicle. Upon activation the LHR couples to numerous G-proteins resulting in the stimulation of the cyclic adenosine monophosphate (cAMP) and inositol-phosphate signaling cascades followed by reprogramming of the cells. The luteinization of the granulosa and theca cells leads to a rupture of the mature follicle and a release of the fertilizable oocyte."
In addition to the background information obtained for this patent, NewsRx journalists also obtained the inventors' summary information for this patent: "The invention relates to a semipermeable microcapsule consisting of a polymer degradable by a polypeptide comprising a genetically engineered cell expressing said polypeptide in response to a triggering compound, and optionally one or more compounds of interest.
"In a particular embodiment the polymer is cellulose or a cellulose derivate and the polypeptide is cellulase.
"The preferred polymer is cellulose sulfate/poly-diallyl-dimethyl-ammonium chloride, or cellulose sulfate modified with carboxymethyl cellulose/poly-diallyl-dimethyl-ammonium chloride. Such microcapsules are non-toxic, do not elicit an immunological response and have an extended half-life time in mammals. They are permeable for compounds with a molecular weight below 20-50 kDA.
"In one embodiment, the microcapsules according to the invention comprise cells expressing cellulase wherein the expression system and corresponding triggering compound is TET and doxycycline, or
"In another embodiment, the microcapsule according to the invention comprise cells expressing cellulase wherein the expression system and corresponding triggering compound is luteinizing hormone receptor, preferably rat luteinizing hormone receptor, and luteinizing hormone.
"Such microcapsules are useful to carry therapeutic compounds to be set free on adding a triggering compound activating expression of the polypeptide, for example cellulase in one of the preferred embodiments. The compound of interest may also be expressed and secreted by an encapsulated genetically engineered cell responding to the same or a different triggering compound, e.g. an endogenous hormone or signalling compound.
"The invention further relates to a method of treating a disease comprising administering to a patient in need thereof a therapeutically effective amount of a microcapsule consisting of a polymer degradable by a polypeptide comprising a therapeutic drug against the disease and a cell expressing the polypeptide triggered by a signalling compound for the disease.
"The invention further relates to a method of artificial insemination comprising administering to a female animal an effective amount of a microcapsule consisting of a polymer degradable by a polypeptide comprising sperm and a cell expressing the polypeptide triggered by luteinizing hormone, and optionally another cell expressing annexins, preferably annexin 1 or 5, to promote binding and prolong the survival time of sperm."
URL and more information on this patent, see: Kemmer, Christian; Fluri, David; Witschi, Ulrich; Weber, Wilfried; Fussenegger, Martin. Degradable Microcapsules. U.S. Patent Number 8506950, filed
Keywords for this news article include: Drugs, Anions, Therapy, Chemicals, Chemistry, Treatment, Cellulases, ETH Zurich, Technology, Erythromycin, Glucosidases, Legal Issues, Bioengineering, Topical Agents, Peptide Hormones, Ammonium Chloride, Hydrochloric Acid, Pituitary Hormones, Genetic Engineering, Luteinizing Hormone, Topical Acne Agents.
Our reports deliver fact-based news of research and discoveries from around the world. Copyright 2013, NewsRx LLC
Most Popular Stories
- Bipartisan Budget Deal Gets Key Support in House
- Bitcoin Clones Lurch Onto Financial Scene
- Clinton to Keynote Annual Simmons Leadership Conference
- Selena Gomez, Shakira Among Top Hispanic Searches
- PhD Project Grooms Business Profs
- Futures Fall, Holiday Spending and Unemployment Up
- GM to Stop Making Autos in Australia
- Budget Deal Will Cut 220,000 Californians Out of Jobless Benefits
- Oil Nears $98 a Barrel
- Senate Not So Keen on Budget Deal